Exelixis is a biotechnology company that develops and commercializes innovative medicines for the treatment of cancer. The company's flagship product, CABOMETYX® (cabozantinib), is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGFR, which are involved in the growth and spread of cancer cells. CABOMETYX is approved in the United States for the treatment of advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC), and is also approved in the European Union and other countries for the treatment of advanced RCC. Exelixis is headquartered in Alameda, California, and has additional offices in South San Francisco, California, and Basel, Switzerland. Learn more at www.exelixis.com.